Catherine M. Szyman Sells 700 Shares of Edwards Lifesciences Corp (EW) Stock

Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the transaction, the vice president now directly owns 27,772 shares of the company’s stock, valued at approximately $3,961,398.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of NYSE:EW opened at $148.63 on Thursday. The firm has a market cap of $36.45 billion, a price-to-earnings ratio of 39.11, a P/E/G ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company had revenue of $972.00 million during the quarter, compared to analyst estimates of $968.32 million. During the same quarter last year, the business posted $1.08 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Bank Hapoalim BM lifted its stake in shares of Edwards Lifesciences by 10.4% in the 2nd quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock valued at $543,000 after purchasing an additional 350 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Edwards Lifesciences by 2.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock valued at $2,378,000 after purchasing an additional 355 shares during the last quarter. Wendell David Associates Inc. lifted its stake in shares of Edwards Lifesciences by 4.0% in the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after purchasing an additional 363 shares during the last quarter. Park Avenue Securities LLC lifted its stake in shares of Edwards Lifesciences by 9.6% in the 2nd quarter. Park Avenue Securities LLC now owns 4,411 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 387 shares during the last quarter. Finally, Tyers Asset Management LLC lifted its stake in shares of Edwards Lifesciences by 6.1% in the 2nd quarter. Tyers Asset Management LLC now owns 6,832 shares of the medical research company’s stock valued at $995,000 after purchasing an additional 392 shares during the last quarter. 82.10% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Saturday, July 14th. Guggenheim reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $168.00 price objective on shares of Edwards Lifesciences in a research note on Friday, July 27th. SunTrust Banks decreased their price objective on shares of Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Finally, ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and a consensus price target of $154.70.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: What strategies should day traders use to execute a trade?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply